Lord Abbett & CO. LLC reduced its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 28.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,207,277 shares of the biotechnology company's stock after selling 887,180 shares during the quarter. Lord Abbett & CO. LLC owned about 0.93% of ADMA Biologics worth $37,855,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 967 shares in the last quarter. Mark Sheptoff Financial Planning LLC purchased a new position in ADMA Biologics in the 4th quarter worth $35,000. Vision Financial Markets LLC acquired a new stake in ADMA Biologics during the 4th quarter worth about $51,000. AlphaQuest LLC purchased a new stake in ADMA Biologics during the 4th quarter valued at about $84,000. Finally, CIBC Private Wealth Group LLC increased its holdings in shares of ADMA Biologics by 137.1% in the fourth quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after purchasing an additional 2,954 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.
ADMA Biologics Stock Performance
NASDAQ ADMA traded down $0.24 on Thursday, reaching $23.56. 1,192,961 shares of the company's stock traded hands, compared to its average volume of 3,679,848. ADMA Biologics, Inc. has a fifty-two week low of $6.52 and a fifty-two week high of $25.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The firm has a market cap of $5.60 billion, a price-to-earnings ratio of 83.88 and a beta of 0.53. The stock has a 50 day moving average price of $19.29 and a 200-day moving average price of $18.40.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.
Get Our Latest Report on ADMA Biologics
ADMA Biologics Company Profile
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Read More
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
